Method of treating symptoms of microbial infection or sepsis

• US 6,011,030 A
• Filed: 09/22/1997
• Issued: 01/04/2000
• Est. Priority Date: 09/22/1997
• Status: Expired due to Term

• Current Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Original Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Inventors: Pfirrmann, Rolf W.
• Primary Examiner(s): SCHEINER, LAURIE A
• Application Number:
  US08/934,753
• Time in Patent Office: 834 Days
• Field of Search: 514/222.2
• US Class Current: 514/222.2
• CPC Class Codes: A61K 31/54 having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
• CPC Class Codes: A61K 31/541 Non-condensed thiazines containing further heterocyclic rings

Abstract

In accordance with the present invention, a method of treating a patient with symptoms of microbial infection and/or sepsis involves first administering to the patient an antimicrobial amount of a cell wall constituent-inactivating, endotoxin non-releasing, and/or exotoxin-inactivating antimicrobial compound such as Taurolidine and/or Taurultam, without administration of an antibiotic to the patient and prior to administration of such antibiotic. The Taurolidine and/or Taurultam are administered locally or intravenously to the patient to substantially inactivate microbes that are causing the infection. Only after substantially inactivating the microbes causing the infection with the Taurolidine and/or Taurultam, is an antibiotic administered to the patient.

Claims

1. A method of treating a patient with bacterial infection, so as to prevent release of bacterial endo-toxins, comprising:

a) identifying a patient exhibiting symptoms of infection by bacteria, said bacteria having bacterial endotoxins;

b) administering to said patient an antimicrobial amount of an antimicrobial compound which is selected from the group consisting of non-antibiotic antimicrobial compounds which are cell wall constituent-inactivating by cell wall crosslinking, non-antibiotic antimicrobial compounds which are endotoxin non-releasing, non-antibiotic antimicrobial compounds which are exotoxin-inactivating, and combinations thereof, without administration of an antibiotic to said patient and prior to substantial administration of any antibiotic to said patient subsequent to step a) above, so as to substantially inactivate said bacteria without releasing said endo-toxins and substantially reduce said symptoms; and

c) then, after substantially inactivating in step b) said bacteria without releasing said endo-toxins and substantially reducing said symptoms with said antimicrobial compound, administering an antibiotic to said patient.

2. The method of claim 1 wherein step a) comprises identifying in said patient symptoms of severe sepsis resulting from infection by gram-negative bacteria, and wherein in step b) said gram-negative bacteria is substantially inactivated without releasing said endo-toxins, and further wherein said antimicrobial compound is a bacterial cell wall-crosslinking compound with bacterial antitoxin activity.

3. The method of claim 1 wherein said antimicrobial compound is selected from a group consisting of Taurolidine, Taurultam and a mixture thereof.

5. The method of claim 1 wherein between step b) and c), a source of said infection is surgically removed from said patient.

6. The method of claim 1 wherein between step b) and c), toxic amounts of purulent material resulting from said infection are removed from said patient.

7. The method of claim 3 wherein said antimicrobial compound is administered substantially continuously for a time period of about 3-5 days prior to the administration of said antibiotic.

8. The method of claim 7 wherein said antimicrobial compound is administered in an aqueous solution at a concentration of about 0.1-3% by weight.

9. The method of claim 8 wherein said aqueous solution of said antimicrobial compound is administered during said time period in a total amount of about 0.5-5 liters.

10. The method of claim 8 wherein said aqueous solution is administered so as to provide said patient with an amount of said antimicrobial compound corresponding to about 20-30 grams/24 hours/adult human patient of Taurolidine.

11. The method of claim 9 wherein said antimicrobial compound is administered intravenously.

12. The method of claim 9 wherein said antimicrobial compound is administered locally at a site of said infection, by catheter introduction.

4. The method of claim I wherein during step c), said antimicrobial compound is co-administered with said antibiotic.